Galapagos (NASDAQ:GLPG) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Saturday.
A number of other research analysts also recently issued reports on GLPG. Zacks Investment Research downgraded Galapagos from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine downgraded Galapagos from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Royal Bank of Canada assumed coverage on Galapagos in a report on Thursday, September 14th. They set a “sector perform” rating and a $98.00 price target on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $123.00 price target (up from $92.00) on shares of Galapagos in a report on Friday, October 6th. Finally, Stifel Nicolaus upped their price target on Galapagos from $101.00 to $120.00 and gave the company a “buy” rating in a report on Friday, September 15th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $111.00.
Shares of Galapagos (NASDAQ:GLPG) traded down $0.98 during trading hours on Friday, hitting $93.76. The stock had a trading volume of 62,253 shares, compared to its average volume of 107,429. The company has a market capitalization of $4,825.75, a P/E ratio of -101.91 and a beta of 1.57. Galapagos has a 1 year low of $63.69 and a 1 year high of $104.12.
ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/30/galapagos-glpg-stock-rating-upgraded-by-bidaskclub.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.